CureVac’s Independent Journey Concludes with BioNTech Acquisition

The final chapter has closed for CureVac as a publicly traded entity. The German biotech firm, once a beacon of hope from Tübingen, has been fully integrated into Mainz-based BioNTech as a wholly-owned subsidiary. This organizational restructuring was finalized on January 6, 2026, following a successful exchange offer, marking an irreversible departure for investors as trading in the stock has been suspended.

Operational Challenges Preceded the Merger

The merger concludes a period defined by significant operational headwinds. While CureVac’s shares posted a 41% gain in their final year of trading, outperforming the S&P 500’s 18.2% rise, this surge was primarily driven by the approximately 55% takeover premium. Fundamentally, the company faced a stark 92% revenue decline from its GSK collaboration in the first half of 2025. A stringent cost-cutting initiative, which included reducing its workforce by 30%, was implemented to secure liquidity through 2028.

Despite these earnings challenges, CureVac contributes valuable assets to BioNTech. These include a cash position of roughly €392.7 million (as of mid-2025) and a strong standing in the expanding lipid nanoparticle market, a point confirmed by a recent industry report.

Transaction Details and Market Mechanics

The takeover proceeded after the acceptance period concluded on December 18, 2025. By that deadline, shareholders had tendered approximately 86.75% of the outstanding shares. The agreed exchange ratio was set at 0.05363 BioNTech American Depositary Shares (ADSs) for each CureVac share.

Should investors sell immediately? Or is it worth buying CureVac?

Consequently, Nasdaq halted trading before the market opened on January 6. Formal delisting is expected on the upcoming Friday, January 16, while the Vienna Stock Exchange removed the listing a day earlier, on January 7.

Market data indicates the window for arbitrage opportunities narrowed rapidly in the deal’s final stages. The short interest ratio plummeted from 2.7% to 0.44% of the free float by the end of 2025, reflecting market participants’ confidence in the transaction’s smooth execution.

Looking Ahead: Integration and Future Value

With its integration into BioNTech, the independent valuation of CureVac’s development pipeline has ended. Investor focus now shifts to operational updates from the parent company and how assets will be prioritized—including anticipated glioblastoma data expected by mid-2026. For former CureVac shareholders, the value of their investment is now entirely tied to the market performance of BioNTech stock.